[Effect of chronic administration of an acylamino alcoyl derivative of benzoic acid, HB 699, on the pancreatic polypeptide secretion in the dog].
HB 699, a hypoglycemic and insulin stimulating agent, which does not belong to the sulphonylurea group, was administered per os to the dog at the dose of 15 mg/kg, daily for 14 days. This agent induced an increase in fasting plasma levels of pancreatic polypeptide, without modifying blood glucose, insulin, glucagon and somatostatin levels.
D000284:Administration, Oral; D000818:Animals; D001549:Benzamides / Q000008:administration & dosage / Q000494:pharmacology*; D004285:Dogs; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D008134:Long-Term Care; D010191:Pancreatic Polypeptide / Q000378:metabolism*
D001549:Benzamides; D007004:Hypoglycemic Agents; D010191:Pancreatic Polypeptide; C030516:meglitinide
Effet de l'administration chronique d'un dérivé acylamino alcoyl de l'acide benzoïque, le HB 699, sur la sécrétion de polypeptide pancréatique chez le chien.